Fulcrum Therapeutics, Inc.
NASDAQ:FULC
3.64 (USD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 2.805 | 6.342 | 19.163 | 8.823 | 0 | 0 | 0 |
| Cost of Revenue
| 2.172 | 2.414 | 2.515 | 2.379 | 2.053 | 1.345 | 0.715 |
| Gross Profit
| 0.633 | 3.928 | 16.648 | 6.444 | -2.053 | -1.345 | -0.715 |
| Gross Profit Ratio
| 0.226 | 0.619 | 0.869 | 0.73 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 71.801 | 76.782 | 69.701 | 59.042 | 71.072 | 25.184 | 18.494 |
| General & Administrative Expenses
| 41.668 | 41.694 | 30.516 | 21.392 | 13.145 | 8.314 | 4.499 |
| Selling & Marketing Expenses
| -2.172 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 39.496 | 41.694 | 30.516 | 21.392 | 13.145 | 8.314 | 4.499 |
| Other Expenses
| 13.329 | 2.69 | 0.207 | 0.792 | 0.029 | 0.392 | 0.028 |
| Operating Expenses
| 111.297 | 118.476 | 100.217 | 80.434 | 84.217 | 33.498 | 22.993 |
| Operating Income
| -110.664 | -112.561 | -81.054 | -71.611 | -84.217 | -33.498 | -22.993 |
| Operating Income Ratio
| -39.452 | -17.749 | -4.23 | -8.116 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 13.329 | 2.69 | 0.207 | 0.792 | 1.54 | 0.392 | 0.028 |
| Income Before Tax
| -97.335 | -109.871 | -80.847 | -70.819 | -82.677 | -32.588 | -22.964 |
| Income Before Tax Ratio
| -34.701 | -17.324 | -4.219 | -8.027 | 0 | 0 | 0 |
| Income Tax Expense
| 2.004 | -4.25 | -2.515 | -2.379 | -3.564 | 0.91 | -0.001 |
| Net Income
| -97.335 | -105.621 | -78.332 | -68.44 | -79.113 | -32.588 | -22.964 |
| Net Income Ratio
| -34.701 | -16.654 | -4.088 | -7.757 | 0 | 0 | 0 |
| EPS
| -1.59 | -2.35 | -2.22 | -2.7 | -7.16 | -1.92 | -2.1 |
| EPS Diluted
| -1.59 | -2.35 | -2.22 | -2.7 | -7.16 | -1.92 | -2.1 |
| EBITDA
| -108.492 | -111.707 | -81.054 | -71.611 | -84.217 | -32.153 | -22.278 |
| EBITDA Ratio
| -38.678 | -17.614 | -4.23 | -8.116 | 0 | 0 | 0 |